Ferroptosis-IN-24
Ferroptosis-IN-24 is a non-classical ferroptosis inhibitor capable of crossing the blood-brain barrier, with nanomolar inhibitory activity against ferroptosis induced by RSL3 (HY-100218A) and Erastin (HY-15763). Ferroptosis-IN-24 alleviates oxidative stress, reduces lipid peroxidation accumulation, and restores redox homeostasis. Ferroptosis-IN-24 is applicable to research related to cerebral ischemia-reperfusion injury and acute liver injury.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 3126217-49-7
- Fòrmula: C18H15NO3
- Peso molecular:293.32
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Actividad biológica
Descripciòn
In Vitro
Ferroptosis-IN-24 (compound D12) (6.25-12.5 μM; 24 h) potently inhibits RSL3 (HY-100218A)-induced ferroptosis in PC12 cells, with an EC50 of 39.7 nM; at concentrations of 6.25 μM and 12.5 μM, it increases cell viability to 90.7% and 96.5%, respectively[1].
Ferroptosis-IN-24 (24 h) inhibits Erastin (HY-15763)-induced ferroptosis in PC12 cells, with an EC50 of 410.4 nM[1].
Ferroptosis-IN-24 (1 μM; 8 h) effectively reduces RSL3-induced intracellular ROS accumulation in PC12 cells[1].
Ferroptosis-IN-24 (1 μM; 8 h) effectively inhibits RSL3-induced lipid peroxidation in PC12 cells[1].
Ferroptosis-IN-24 (1 μM; 6 h) reverses the RSL3-induced downregulation of GPX4 and Nrf2 protein expression in PC12 cells[1].
Ferroptosis-IN-24 (1 μM) reduces the stress-induced overexpression of GPX4, Nrf2, HMOX1 and NQO1 mRNA in RSL3-treated PC12 cells, indicating that it alleviates upstream oxidative stress rather than directly activating the Nrf2 pathway[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:PC12 cells (RSL3-induced ferroptosis)
-
Concentration:6.25 μM; 12.5 μM
-
Incubation Time:24 h
-
Result:Increased PC12 cell viability to 90.7% under RSL3-induced ferroptosis conditions at 6.25 μM.
Increased cell viability to 96.5% under RSL3-induced ferroptosis conditions at 12.5 μM.
-
Cell Line:PC12 cells (RSL3-treated)
-
Concentration:1 μM
-
Incubation Time:6 h
-
Result:Reversed the RSL3-induced downregulation of GPX4 protein levels in PC12 cells, restoring expression to near-control levels.
Reversed the RSL3-induced downregulation of Nrf2 protein levels in PC12 cells, restoring expression to near-control levels.
Parmacokinetics
| Species | Dose | Route | Cmax | Tmax | AUC0-∞ | T1/2 | V | CL | AUC0-t |
|---|---|---|---|---|---|---|---|---|---|
| Rat[1] | 10 mg/kg | i.v. | 8199.91 μg/L | 0.08 h | 4208.09 μg/L·h | 4.76 h | 0.53 L/kg | 2.38 L/h/kg | 3350.27 μg/L·h |
In Vivo
Ferroptosis-IN-24 (10 mg/kg; i.v.; single pretreatment) reduces the cerebral infarction volume and improves neurological deficits in a rat model of cerebral ischemia-reperfusion injury induced by MCAO[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, APAP-induced acute liver injury model)[1]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:i.p.; single pretreatment (1 h before APAP challenge)
-
Result:Reduced liver necrosis dose-dependently, with near-normal liver histology at 20 mg/kg.
Reduced serum alanine transaminase (ALT) level and aspartate transaminase (AST) level.
Restored hepatic glutathione (GSH) level.
Reduced malondialdehyde (MDA) level.
-
Animal Model:SD (male, MCAO-induced cerebral ischemia-reperfusion injury model)[1]
-
Dosage:10 mg/kg
-
Administration:i.v.; single pretreatment (1 h before MCAO, followed by 24 h reperfusion)
-
Result:Reduced cerebral infarct volume.
Improved neurological deficits.
Chemical Information
-
No. CAS 3126217-49-7
-
Peso molecular 293.32
-
Fòrmula C18H15NO3
-
SMILES
O=C(C1=CC(OC(C)=O)=C2N1C=CC=C2)C3=CC=CC=C3C
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocolo
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)